219 related articles for article (PubMed ID: 19420766)
21. Multifunctional enveloped nanodevices (MENDs).
Sato Y; Nakamura T; Yamada Y; Akita H; Harashima H
Adv Genet; 2014; 88():139-204. PubMed ID: 25409606
[TBL] [Abstract][Full Text] [Related]
22. Improved Stability of siRNA-Loaded Lipid Nanoparticles Prepared with a PEG-Monoacyl Fatty Acid Facilitates Ligand-Mediated siRNA Delivery.
Sakurai Y; Mizumura W; Ito K; Iwasaki K; Katoh T; Goto Y; Suga H; Harashima H
Mol Pharm; 2020 Apr; 17(4):1397-1404. PubMed ID: 32091909
[TBL] [Abstract][Full Text] [Related]
23. Efficient siRNA delivery using novel siRNA-loaded Bubble liposomes and ultrasound.
Endo-Takahashi Y; Negishi Y; Kato Y; Suzuki R; Maruyama K; Aramaki Y
Int J Pharm; 2012 Jan; 422(1-2):504-9. PubMed ID: 22119963
[TBL] [Abstract][Full Text] [Related]
24. Multifunctional Envelope-Type Nano Device: Evolution from Nonselective to Active Targeting System.
Hayashi Y; Hatakeyama H; Kajimoto K; Hyodo M; Akita H; Harashima H
Bioconjug Chem; 2015 Jul; 26(7):1266-76. PubMed ID: 25938819
[TBL] [Abstract][Full Text] [Related]
25. Peptide-based targeted polymeric nanoparticles for siRNA delivery.
Hussein WM; Cheong YS; Liu C; Liu G; Begum AA; Attallah MA; Moyle PM; Torchilin VP; Smith R; Toth I
Nanotechnology; 2019 Oct; 30(41):415604. PubMed ID: 31295734
[TBL] [Abstract][Full Text] [Related]
26. In vitro investigations of the efficacy of cyclodextrin-siRNA complexes modified with lipid-PEG-Octaarginine: towards a formulation strategy for non-viral neuronal siRNA delivery.
O'Mahony AM; Desgranges S; Ogier J; Quinlan A; Devocelle M; Darcy R; Cryan JF; O'Driscoll CM
Pharm Res; 2013 Apr; 30(4):1086-98. PubMed ID: 23192687
[TBL] [Abstract][Full Text] [Related]
27. Conjugates of HA2 with octaarginine-grafted HPMA copolymer offer effective siRNA delivery and gene silencing in cancer cells.
Golan M; Feinshtein V; David A
Eur J Pharm Biopharm; 2016 Dec; 109():103-112. PubMed ID: 27702685
[TBL] [Abstract][Full Text] [Related]
28. [Development of an efficient short interference RNA (siRNA) delivery system with a new pH-sensitive cationic lipid].
Sato Y; Hatakeyama H; Hyodo M; Akita H; Harashima H
Yakugaku Zasshi; 2012; 132(12):1355-63. PubMed ID: 23208041
[TBL] [Abstract][Full Text] [Related]
29. Efficient siRNA Delivery by Lipid Nanoparticles Modified with a Nonstandard Macrocyclic Peptide for EpCAM-Targeting.
Sakurai Y; Mizumura W; Murata M; Hada T; Yamamoto S; Ito K; Iwasaki K; Katoh T; Goto Y; Takagi A; Kohara M; Suga H; Harashima H
Mol Pharm; 2017 Oct; 14(10):3290-3298. PubMed ID: 28789523
[TBL] [Abstract][Full Text] [Related]
30. Engineering of small interfering RNA-loaded lipidoid-poly(DL-lactic-co-glycolic acid) hybrid nanoparticles for highly efficient and safe gene silencing: A quality by design-based approach.
Thanki K; Zeng X; Justesen S; Tejlmann S; Falkenberg E; Van Driessche E; Mørck Nielsen H; Franzyk H; Foged C
Eur J Pharm Biopharm; 2017 Nov; 120():22-33. PubMed ID: 28756280
[TBL] [Abstract][Full Text] [Related]
31. Reducing the Cytotoxicity of Lipid Nanoparticles Associated with a Fusogenic Cationic Lipid in a Natural Killer Cell Line by Introducing a Polycation-Based siRNA Core.
Nakamura T; Yamada K; Fujiwara Y; Sato Y; Harashima H
Mol Pharm; 2018 Jun; 15(6):2142-2150. PubMed ID: 29668291
[TBL] [Abstract][Full Text] [Related]
32. A DNA microarray-based analysis of immune-stimulatory and transcriptional responses of dendritic cells to KALA-modified nanoparticles.
Akita H; Ishii S; Miura N; Shaheen SM; Hayashi Y; Nakamura T; Kaji N; Baba Y; Harashima H
Biomaterials; 2013 Nov; 34(35):8979-90. PubMed ID: 23968857
[TBL] [Abstract][Full Text] [Related]
33. Advantages of ethanol dilution method for preparing GALA-modified liposomal siRNA carriers on the in vivo gene knockdown efficiency in pulmonary endothelium.
Kusumoto K; Akita H; Santiwarangkool S; Harashima H
Int J Pharm; 2014 Oct; 473(1-2):144-7. PubMed ID: 24998506
[TBL] [Abstract][Full Text] [Related]
34. Multifunctional peptide-lipid nanocomplexes for efficient targeted delivery of DNA and siRNA into breast cancer cells.
Wan Y; Dai W; Nevagi RJ; Toth I; Moyle PM
Acta Biomater; 2017 Sep; 59():257-268. PubMed ID: 28655658
[TBL] [Abstract][Full Text] [Related]
35. Failure of active targeting by a cholesterol-anchored ligand and improvement by altering the lipid composition to prevent ligand desorption.
Yamamoto S; Sakurai Y; Harashima H
Int J Pharm; 2018 Jan; 536(1):42-49. PubMed ID: 29126905
[TBL] [Abstract][Full Text] [Related]
36. DOTAP functionalizing single-walled carbon nanotubes as non-viral vectors for efficient intracellular siRNA delivery.
Li H; Hao Y; Wang N; Wang L; Jia S; Wang Y; Yang L; Zhang Y; Zhang Z
Drug Deliv; 2016; 23(3):840-8. PubMed ID: 24892622
[TBL] [Abstract][Full Text] [Related]
37. Efficient and High-Speed Transduction of an Antibody into Living Cells Using a Multifunctional Nanocarrier System to Control Intracellular Trafficking.
Yamada Y; Perez SM; Tabata M; Abe J; Yasuzaki Y; Harashima H
J Pharm Sci; 2015 Sep; 104(9):2845-54. PubMed ID: 25546552
[TBL] [Abstract][Full Text] [Related]
38. Endosomal escape and the knockdown efficiency of liposomal-siRNA by the fusogenic peptide shGALA.
Sakurai Y; Hatakeyama H; Sato Y; Akita H; Takayama K; Kobayashi S; Futaki S; Harashima H
Biomaterials; 2011 Aug; 32(24):5733-42. PubMed ID: 21605898
[TBL] [Abstract][Full Text] [Related]
39. GALA-Modified Lipid Nanoparticles for the Targeted Delivery of Plasmid DNA to the Lungs.
Hagino Y; Khalil IA; Kimura S; Kusumoto K; Harashima H
Mol Pharm; 2021 Mar; 18(3):878-888. PubMed ID: 33492961
[TBL] [Abstract][Full Text] [Related]
40. Functional improvement of an IRQ-PEG-MEND for delivering genes to the lung.
Ishitsuka T; Akita H; Harashima H
J Control Release; 2011 Aug; 154(1):77-83. PubMed ID: 21619903
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]